Safety of L-proline as a stabilizer for immunoglobulin products

References

• Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev. Clin. Immunol.7(3), 301–316 (2011).
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin. Exp. Immunol.164(Suppl. 2), 16–19 (2011).
   PubMedGoogle Scholar
• Krane SM. The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. Amino Acids35(4), 703–710 (2008).
   PubMed Web of Science ®Google Scholar
• Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids37(1), 1–17 (2009).
   PubMed Web of Science ®Google Scholar
• Tomlinson C, Rafii M, Sgro M, Ball RO, Pencharz P. Arginine is synthesized from proline, not glutamate, in enterally fed human preterm neonates. Pediatr. Res.69(1), 46–50 (2011).
   PubMedGoogle Scholar
• Wu A. Tietz Clinical Guide to Laboratory Tests (4th Edition). Saunders, PA, USA (2006).
   Google Scholar
• Voet D, Voet JG. Biochemistry (2nd Edition). John Wiley & Sons, Inc., NJ, USA (1995).
   Google Scholar
• Cohen SM, Nadler JV. Proline-induced potentiation of glutamate transmission. Brain Res.761(2), 271–282 (1997).
   PubMedGoogle Scholar
• Krishnan N, Dickman MB, Becker DF. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic. Biol. Med.44(4), 671–681 (2008).
   PubMed Web of Science ®Google Scholar
• Washington JM, Rathjen J, Felquer F et al.L-proline induces differentiation of ES cells: a novel role for an amino acid in the regulation of pluripotent cells in culture. Am. J. Physiol. Cell Physiol.298(5), C982–C992 (2010).
   PubMedGoogle Scholar
• Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J. Infus. Nurs.28(6), 366–374 (2005).
   PubMedGoogle Scholar
• Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev.58(5–6), 686–706 (2006).
   PubMed Web of Science ®Google Scholar
• Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals31(4), 277–286 (2003).
   PubMedGoogle Scholar
• Berger M. L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use. Immunotherapy3(2), 163–176 (2011).
   PubMed Web of Science ®Google Scholar
• Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin. Vox Sang.7, 157–174 (1962).
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Agterberg J, Rigter G, van Rooijen N, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin. Exp. Immunol.77(3), 338–344 (1989).
   PubMedGoogle Scholar
• Andresen I, Kovarik JM, Spycher M, Bolli R. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. J. Clin. Pharmacol.40(7), 722–730 (2000).
   PubMed Web of Science ®Google Scholar
• Szenczi A, Kardos J, Medgyesi GA, Zavodszky P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals34(1), 5–14 (2006).
   PubMed Web of Science ®Google Scholar
• Bolli R, Woodtli K, Bartschi M, Hofferer L, Lerch P. L-proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals38(1), 150–157 (2010).
   PubMed Web of Science ®Google Scholar
• Maeder W, Lieby P, Sebald A, Spycher M, Pedrussio R, Bolli R. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals39(1), 43–49 (2011).
   PubMedGoogle Scholar
• Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline. Vox Sang.96(3), 219–225 (2009).
   PubMed Web of Science ®Google Scholar
• Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline. Vox Sang.96(3), 219–225 (2009).
   PubMed Web of Science ®Google Scholar
• Hizentra (Immune Globulin Subcutaneous (Human), 20% Liquid). Full prescribing information, CSL Behring, LLC, IL, USA (2011).
   Google Scholar
• Privigen (Immune Globulin Intravenous (Human), 10% Liquid). Full prescribing information, CSL Behring, LLC, IL, USA (2011).
   Google Scholar
• Privigen (human normal immunoglobulin). EPAR-product information, CSL Behring GmbH, Marburg, Germany (2011).
   Google Scholar
• Hizentra (human normal immunoglobulin [SCIg]). EPAR-Product Information, CSL Behring GmbH, Marburg, Germany (2011).
   Google Scholar
• Phang J, Chien-an A, Valle D. Disorders of proline and hydroxyproline metabolism. In: Disorders of Proline and Hydroxyproline Metabolism (7th Edition). Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A (Eds). McGraw-Hill, NY, USA (2007).
   Google Scholar
• Goodman BK, Rutberg J, Lin WW, Pulver AE, Thomas GH. Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J. Inherit. Metab. Dis.23(8), 847–848 (2000).
   PubMed Web of Science ®Google Scholar
• Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet370(9596), 1443–1452 (2007).
   PubMed Web of Science ®Google Scholar
• McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore).90(1), 1–18 (2011).
   PubMed Web of Science ®Google Scholar
• Shprintzen RJ. Velo-cardio-facial syndrome: 30 years of study. Dev. Disabil. Res. Rev.14(1), 3–10 (2008).
   PubMed Web of Science ®Google Scholar
• Botto LD, May K, Fernhoff PM et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics112(1 Pt 1), 101–107 (2003).
   PubMed Web of Science ®Google Scholar
• Veerapandiyan A, Abdul-Rahman OA, Adam MP et al. Chromosome 22q11.2 deletion syndrome in African-American patients: a diagnostic challenge. Am. J. Med. Genet. A.155(9), 2186–2195 (2011).
   Google Scholar
• Raux G, Bumsel E, Hecketsweiler B et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet.16(1), 83–91 (2007).
   PubMed Web of Science ®Google Scholar
• Lewandowski KE, Shashi V, Berry PM, Kwapil TR. Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(1), 27–36 (2007).
   PubMed Web of Science ®Google Scholar
• McDonald-McGinn DM, LaRossa D, Goldmuntz E et al. The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genet. Test.1(2), 99–108 (1997).
   PubMedGoogle Scholar
• International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature455(7210), 237–241 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Jawad AF, Randall P et al. Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes. Clin. Immunol. Immunopathol.86(2), 141–146 (1998).
   PubMedGoogle Scholar
• Sullivan KE, McDonald-McGinn D, Driscoll DA, Emanuel BS, Zackai EH, Jawad AF. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin. Diagn. Lab. Immunol.6(6), 906–911 (1999).
   PubMedGoogle Scholar
• Ballow M, Notarangelo L, Grimbacher B et al. Immunodeficiencies. Clin. Exp. Immunol.158(Suppl. 1), 14–22 (2009).
   PubMedGoogle Scholar
• Sullivan K. Hypogammaglobulinemia in DiGeorge syndrome: a registry approach. Presented at: Clinical Immunology Society. Chicago, IL, USA, 19–22 May 2011.
   Google Scholar
• Campbell HD, Webb GC, Young IG. A human homologue of the Drosophila melanogaster sluggish-A (proline oxidase) gene maps to 22q11.2, and is a candidate gene for Type-1 hyperprolinaemia. Hum. Genet.101(1), 69–74 (1997).
   PubMed Web of Science ®Google Scholar
• Delwing D, Bavaresco CS, Wannmacher CM, Wajner M, Dutra-Filho CS, Wyse AT. Proline induces oxidative stress in cerebral cortex of rats. Int. J. Dev. Neurosci.21(2), 105–110 (2003).
   PubMed Web of Science ®Google Scholar
• Ferreira AG, Lima DD, Delwing D et al. Proline impairs energy metabolism in cerebral cortex of young rats. Metab. Brain Dis.25(2), 161–168 (2010).
   PubMedGoogle Scholar
• Bavaresco CS, Streck EL, Netto CA, Wyse AT. Chronic hyperprolinemia provokes a memory deficit in the Morris water maze task. Metab. Brain Dis.20(1), 73–80 (2005).
   PubMed Web of Science ®Google Scholar
• Moreira JC, Wannmacher CM, Costa SM, Wajner M. Effect of proline administration on rat behavior in aversive and nonaversive tasks. Pharmacol. Biochem. Behav.32(4), 885–890 (1989).
   PubMed Web of Science ®Google Scholar
• Shanti ND, Shashikumar KC, Desai PV. Influence of proline on rat brain activities of alanine aminotransferase, aspartate aminotransferase and acid phosphatase. Neurochem. Res.29(12), 2197–2206 (2004).
   PubMedGoogle Scholar
• Delwing D, Bavaresco CS, Chiarani F et al.In vivo and in vitro effects of proline on some parameters of oxidative stress in rat brain. Brain Res.991(1–2), 180–186 (2003).
   PubMed Web of Science ®Google Scholar
• Delwing D, Chiarani F, Bavaresco CS et al. Protective effect of antioxidants on brain oxidative damage caused by proline administration. Neurosci. Res.52(1), 69–74 (2005).
   PubMed Web of Science ®Google Scholar
• Adibi SA, Gray SJ, Menden E. The kinetics of amino acid absorption and alteration of plasma composition of free amino acids after intestinal perfusion of amino acid mixtures. Am. J. Clin. Nutr.20(1), 24–33 (1967).
   PubMedGoogle Scholar
• Jaksic T, Wagner DA, Burke JF, Young VR. Plasma proline kinetics and the regulation of proline synthesis in man. Metabolism36(11), 1040–1046 (1987).
   PubMedGoogle Scholar
• Maher TJ, Glaeser BS, Wurtman RJ. Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: effects of dietary protein intake. Am. J. Clin. Nutr.39(5), 722–729 (1984).
   PubMedGoogle Scholar
• Stein MR, Nelson RP, Church JA et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol.29(1), 137–144 (2009).
   PubMed Web of Science ®Google Scholar
• Hayasaka S, Saito T, Nakajima H, Takahashi O, Mizuno K, Tada K. Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina. Br. J. Ophthalmol.69(4), 283–290 (1985).
   PubMedGoogle Scholar
• Scriver CR, Efron ML, Schafer IA. Renal tubular transport of proline, hydroxyproline, and glycine in health and in familial hyperprolinemia. J. Clin. Invest.43, 374–385 (1964).
   PubMedGoogle Scholar
• Robak T, Salama A, Kovaleva L et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology14(4), 227–236 (2009).
   PubMed Web of Science ®Google Scholar
• Hagan JB, Fasano MB, Spector S et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J. Clin. Immunol.30(5), 734–745 (2010).
   PubMed Web of Science ®Google Scholar
• Jacquet H, Berthelot J, Bonnemains C et al. The severe form of Type 1 hyperprolinaemia results from homozygous inactivation of the PRODH gene. J. Med. Genet.40(1), e7 (2003).
   PubMedGoogle Scholar
• Afenjar A, Moutard ML, Doummar D et al. Early neurological phenotype in 4 children with biallelic PRODH mutations. Brain Dev.29(9), 547–552 (2007).
   PubMedGoogle Scholar
• Bender HU, Almashanu S, Steel G et al. Functional consequences of PRODH missense mutations. Am. J. Hum. Genet.76(3), 409–420 (2005).
   PubMed Web of Science ®Google Scholar
• Clelland CL, Read LL, Baraldi AN et al. Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. Schizophr. Res.131(1–3), 139–145 (2011).
   PubMedGoogle Scholar
• Jacquet H, Demily C, Houy E et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol. Psychiatr.10(5), 479–485 (2005).
   PubMed Web of Science ®Google Scholar
• Jacquet H, Rapoport JL, Hecketsweiler B et al. Hyperprolinemia is not associated with childhood onset schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.141B(2), 192 (2006).
   PubMedGoogle Scholar
• Williams HJ, Williams N, Spurlock G et al. Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.120B(1), 42–46 (2003).
   PubMedGoogle Scholar
• Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol.221(6), 1629–1639 (1971).
   PubMed Web of Science ®Google Scholar
• Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T. ATA2 is predominantly expressed as system A at the blood–brain barrier and acts as brain-to-blood efflux transport for L-proline. Mol. Pharmacol.61(6), 1289–1296 (2002).
   PubMedGoogle Scholar
• Humbertclaude V, Rivier F, Roubertie A et al. Is hyperprolinemia Type 1 actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. J. Child Neurol.16(8), 622–623 (2001).
   PubMedGoogle Scholar
• Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J. Clin. Immunol.27(5), 497–502 (2007).
   PubMed Web of Science ®Google Scholar